| P50 | author | Stanisław Jerzy Czuczwar | Q9342142 |
| P2093 | author name string | Patsalos PN | |
| P2860 | cites work | KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel | Q22008501 |
| | The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits | Q28138343 |
| | Genetic absence epilepsy in rats from Strasbourg--a review | Q28260153 |
| | Molecular composition of GABAC receptors | Q28276680 |
| | Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy | Q28292575 |
| | Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy | Q28369868 |
| | Characteristics of a unique visual field defect attributed to vigabatrin | Q28378109 |
| | Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders | Q33594429 |
| | New antiepileptic drugs | Q33660259 |
| | Epidemiology of the epilepsies | Q33735546 |
| | Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor | Q34419382 |
| | The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells | Q34447899 |
| | The new antiepileptic drugs: a systematic review of their efficacy and tolerability | Q74526025 |
| | Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV) | Q77292948 |
| | Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity | Q34467392 |
| | Visual field defects associated with vigabatrin therapy | Q35454439 |
| | Response to vigabatrin in relation to seizure type | Q38671464 |
| | Gamma-aminobutyric acid and the search for new anticonvulsant drugs | Q39498507 |
| | Mechanism of anticonvulsant action of valproate | Q40090363 |
| | Place of newer antiepileptic drugs in the treatment of epilepsy | Q40387137 |
| | A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor | Q40412354 |
| | Recent advances in the GABA-A-benzodiazepine receptor pharmacology | Q41038011 |
| | The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal | Q41089572 |
| | The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel | Q41217429 |
| | Update on the mechanism of action of antiepileptic drugs | Q41240609 |
| | Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy | Q41733392 |
| | New visions in the pharmacology of anticonvulsion | Q41739650 |
| | Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats | Q42205553 |
| | Inappropriate use of carbamazepine and vigabatrin in typical absence seizures | Q42539564 |
| | The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy | Q42557365 |
| | D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures | Q42638756 |
| | Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). | Q43515162 |
| | Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina. | Q43684847 |
| | Vigabatrin in childhood epilepsy: comparable efficacy for generalized and partial seizures | Q45099737 |
| | Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group. | Q46039957 |
| | Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic gaba and gamma-vinyl GABA, two irreversible GABA-T inhibitors | Q46931919 |
| | Vigabatrin as a first-line drug in West syndrome: clinical and electroencephalographic outcome | Q47677423 |
| | Effects of GABAB receptor antagonism on the development of pentylenetetrazol-induced kindling in mice | Q48329249 |
| | Tiagabine: a novel antiepileptic drug | Q48344925 |
| | Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin | Q48369138 |
| | Topiramate increases cerebral GABA in healthy humans | Q48408666 |
| | Behavioral effects of vigabatrin correlated with whole brain gamma-aminobutyric acid metabolism in audiogenic sensitive rats. | Q48410385 |
| | Opposite effects of GABAB receptor antagonists on absences and convulsive seizures | Q48637716 |
| | Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain | Q48687083 |
| | Effect of anticonvulsant felbamate on GABAA receptor system | Q48737362 |
| | Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose | Q48984004 |
| | Elevation of γ-aminobutyric acid in brain with amino-oxyacetic acid and susceptibility to convulsive seizures in mice: A quantitative re-evaluation | Q51238349 |
| | Ganaxolone, a selective, high-affinity steroid modulator of the gamma-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence. | Q51496878 |
| | The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro. | Q51589015 |
| | Long-term follow-up study of vigabatrin in pretreated children with West syndrome. | Q51991463 |
| | Effects of GABAB receptor antagonists on learning and memory retention in a rat model of absence epilepsy. | Q52043868 |
| | The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca ++ and low Mg++ model in the hippocampal slice preparation. | Q53920348 |
| | Topiramate monotherapy for partial onset seizures. | Q53973014 |
| | D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. | Q53989493 |
| | Topiramate: preclinical evaluation of structurally novel anticonvulsant. | Q64998360 |
| | Effects of GABA-ergic agents on spontaneous non-convulsive epilepsy, EEG and behaviour, in the WAG/RIJ inbred strain of rats | Q69757782 |
| | The specific protective effect of diazepam and valproate against isoniazid-induced seizures is not correlated with increased GABA levels | Q69965182 |
| | Receptor and voltage-operated ion channels in the central nervous system | Q71276874 |
| | Effects of the GABAB antagonist CGP 35348 on sleep-wake states, behaviour, and spike-wave discharges in old rats | Q71337324 |
| | Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response | Q71526090 |
| | Effect of Dopaminergic and GABA-ergic Drugs Given Alone or in Combination on the Anticonvulsant Action of Phenobarbital and Diphenylhydantoin in the Electroshock Test in Mice | Q72864990 |
| | Effect of combined treatment with dopaminergic and GABA-ergic drugs on the threshold for maximal electroconvulsions in mice | Q72899907 |
| | Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects | Q73016916 |
| P433 | issue | 5 | |
| P304 | page(s) | 339-350 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | CNS Drugs | Q5013183 |
| P1476 | title | The new generation of GABA enhancers. Potential in the treatment of epilepsy | |
| P478 | volume | 15 | |